pharmaphorum

SEPTEMBER 28, 2022

Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this year. The post Vertex, CRISPR prep filing for gene-editing blood disorder therapy appeared first on.

Gene Editing 59

Gene Editing Gene In-Vivo Clinical Trials 59

XTalks

DECEMBER 13, 2023

Casgevy’s approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the US. In 2022, bluebird won approvals for two gene therapies — Skysona for the treatment of the rare neurological disorder cerebral adrenoleukodystrophy (CALD) and Zynteglo for beta-thalassemia.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

DECEMBER 29, 2022

This highlights potentially new marketing trends that life science companies may have to start looking into if they haven’t already. As of December 16, 2022, there are seven US Food and Drug Administration (FDA) approved gene therapies. In 2023, a number of gene therapies are expected to get the FDA green light.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

JANUARY 10, 2022

The first mRNA-based vaccines were brought onto the market in 2020, with Pfizer/BioNtech and Moderna receiving emergency use authorisation from the US Food and Drug Administration (FDA) for the prevention of COVID-19. Currently, the company is researching two potential therapies in immuno-oncology, both at the phase 1 stage.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

XTalks

DECEMBER 22, 2021

The market for mRNA-based vaccines and therapeutics is projected to grow from $46.7 The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference. The global wearable medical devices market is projected to burgeon to a whopping $195.57

Life Science 98

Life Science RNA Vaccination Vaccine 98

Drug Discovery World

FEBRUARY 22, 2024

But psychopharmacology developments petered out, and few new drugs reached the market during the last four decades. Further, the treatments on offer today often only delay the progression of the disease without recovering lost brain function 4 ”.

Drugs 59

Drugs Gene Clinical Trials Clinical Trials 59